pandem
continu
expand
effect
vaccin
cure
yet
avail
exist
therapi
manag
limit
mortal
control
viral
prolifer
associ
side
effect
cure
diseas
subject
develop
resist
find
new
therapeut
target
drug
therefor
crucial
previous
shown
dendrit
cell
immunoreceptor
dcir
ctype
lectin
receptor
express
dendrit
cell
dc
act
attach
factor
dc
contribut
transmiss
lymphocyt
directli
involv
infect
dcir
express
apoptot
infect
promot
transinfect
bystand
cell
report
model
extracellular
domain
dcir
base
structur
two
surfac
access
pocket
contain
carbohydr
recognit
domain
ep
bind
motif
respect
target
screen
chemic
disrupt
normal
interact
particl
preliminari
screen
use
cell
allow
identif
two
inhibitor
decreas
attach
propag
impact
inhibitor
infect
dc
evalu
well
result
studi
thu
identifi
novel
molecul
capabl
block
transmiss
dc
discoveri
new
therapeut
target
develop
new
therapeut
approach
necessari
order
pursu
fight
human
immunodefici
viru
type
drug
current
avail
develop
treat
infect
target
viru
replic
mechan
thu
risk
select
resist
variant
although
treatment
increas
lifespan
patient
also
contribut
increas
comorbid
studi
simian
model
recent
human
show
treatment
acut
phase
infect
improv
immun
respons
viru
demonstr
earli
event
infect
highli
determin
irrevers
damag
inflict
key
immun
cell
maintain
vital
immun
compet
crucial
find
new
target
involv
first
step
viral
transmiss
prevent
devast
initi
damag
immun
system
first
immun
cell
establish
contact
invad
dendrit
cell
dc
commun
cell
innat
adapt
immun
system
dc
intric
involv
initi
respons
primari
infect
mucos
tissu
first
intern
dc
migrat
secondari
lymphoid
organ
viru
transfer
lymphocyt
transloc
intern
viru
appear
occur
via
celltocel
junction
socal
virolog
synaps
creat
simpl
physic
contact
dc
lead
virion
product
cell
type
transfer
dc
occur
two
distinct
phase
initi
phase
viru
locat
within
endosom
compart
dc
transport
intercellular
junction
intern
later
second
phase
depend
product
infect
dc
storag
viral
progeni
recent
demonstr
ctype
lectin
receptor
known
dendrit
cell
immunoreceptor
dcir
allow
attach
dc
enhanc
infect
phase
unlik
dcsign
dendrit
cellspecif
intercellular
adhes
non
integrin
involv
earli
phase
among
variou
cell
surfac
receptor
express
dc
dcir
shown
play
key
role
viral
dissemin
initi
infect
antivir
immun
furthermor
like
interact
dcir
major
factor
pathogenesi
sinc
dcir
express
induc
apoptosi
previous
shown
apoptosi
indic
pathogenesi
earli
later
phase
aid
view
dcir
express
dc
role
transmiss
vitro
receptor
hold
promis
target
prevent
infect
possibl
decreas
transmiss
chronic
phase
diseas
apoptosi
increas
dcir
express
primarili
cell
myeloid
lineag
ie
neutrophil
dc
monocyt
macrophag
well
b
cell
addit
interact
dcir
like
signific
pathogenesi
sinc
observ
dcir
express
hivload
vitro
patient
well
apoptot
howev
physiolog
function
dcir
fulli
understood
dcir
associ
autoimmun
diseas
dcir
detect
surfac
plasmacytoid
dc
may
regul
dc
expans
myeloid
plasmacytoid
dc
intern
dcir
inhibit
respons
two
tolllik
receptor
known
play
import
role
innat
immun
virus
dcir
product
human
gene
encod
protein
amino
acid
residu
length
uniqu
among
lectin
receptor
due
presenc
sever
uniqu
structur
motif
contain
intracellular
signal
consensu
sequenc
known
immunoreceptor
tyrosinebas
inhibit
motif
itim
neck
domain
import
bind
includ
carbohydr
recognit
domain
crd
extracellular
portion
ep
motif
glupros
specif
galactos
recognit
domain
determin
itim
motif
requir
dcirmedi
enhanc
infect
furthermor
shown
use
antibodi
direct
ep
motif
crd
domain
delet
neck
domain
extracellular
portion
involv
bind
subsequ
transfer
given
potenti
hiv
infect
interact
dcir
object
develop
molecul
inhibit
hiv
bind
dcir
consid
virusencod
viral
envelop
glycoprotein
one
heavili
glycosyl
protein
known
natur
review
vigerust
shepherd
dcsigndepend
captur
requir
interact
crd
domain
dcsign
might
similar
interact
allow
dcir
act
attach
factor
ep
motif
dcir
known
bind
specif
galactosyl
residu
glycoprotein
sinc
galactosyl
residu
present
surfac
design
synthes
chemic
inhibitor
target
ep
andor
crd
domain
dcir
virtual
screen
recent
help
discov
ligand
inhibitor
base
crystallograph
homolog
model
target
protein
studi
shown
virtual
dock
homolog
model
frequent
yield
enrich
known
ligand
good
obtain
dock
crystal
structur
actual
target
protein
structurebas
approach
inhibitor
design
use
identifi
sever
inhibitor
dehydrogenas
rnadepend
rna
polymeras
method
analysi
structur
dcir
requir
design
potent
specif
inhibitor
interact
via
crd
andor
ep
motif
therebi
gener
potenti
new
drug
sinc
complet
partial
tertiari
structur
publish
dcir
built
homolog
model
use
structur
crd
lsign
also
interact
templat
base
model
sever
inhibitor
select
use
virtual
screen
test
use
variou
method
studi
show
specif
chemic
inhibitor
direct
ep
motif
crd
domain
dcir
prevent
attach
dc
apoptot
infect
without
side
effect
prolifer
dcir
homolog
model
addit
provid
detail
structur
inform
help
develop
new
lead
compound
use
virtual
screen
combin
vivo
test
reagent
purchas
r
system
minneapoli
mn
granulocytemacrophag
colonystimul
factor
gmcsf
purchas
genscript
piscataway
nj
cell
grown
routin
rpmi
medium
supplement
fetal
bovin
serum
fb
penicillin
g
uml
streptomycin
mgml
lglutamin
mm
purchas
wisent
bioproduct
stbruno
qc
canada
primocin
amaxa
biosystem
gaithersburg
md
usa
cultur
medium
cell
made
dmem
invitrogen
burlington
canada
supplement
fb
penicillin
g
u
ml
streptomycin
mgml
lglutamin
mm
model
human
dcir
structur
use
swiss
model
homolog
model
program
via
websit
interfac
run
automat
mode
submit
dcir
sequenc
uniprotkbswissprot
access
number
result
model
examin
use
pdb
viewer
program
model
dcir
serv
receptor
dock
studi
hydrophob
pocket
dcir
extracellular
domain
structur
residu
evalu
site
finder
applic
moe
program
chemic
comput
group
montreal
qc
canada
rank
accord
hydrophob
contact
locat
protein
model
inspect
visual
accuraci
x
dihedr
angl
asn
residu
x
angl
gln
rotat
need
maxim
hydrogen
bond
proper
histidinyl
tautom
select
manual
maxim
hydrogen
bond
final
aspartyl
glutamyl
arginyl
lysyl
residu
treat
usual
charg
speci
ligand
dock
dcir
carri
use
genet
optim
ligand
dock
gold
version
ligand
sidechain
flexibl
allow
dock
chemscor
score
function
implement
gold
program
use
estim
chang
free
energi
occur
upon
ligand
bind
protein
chemscor
dg
bind
p
clash
c
intern
p
intern
c
coval
p
coval
p
constraint
dg
bind
dg
dg
hbond
hbond
dg
metal
metal
dg
lipo
lipo
dg
rot
h
rot
p
clash
p
intern
p
coval
p
constraint
penalti
factor
includ
prevent
poor
geometri
dock
due
respect
atom
posit
intern
torsion
constraint
valenceangl
bend
constraint
c
intern
c
coval
scale
factor
respect
penalti
term
hbond
metal
lipo
respect
free
energi
score
account
contribut
hydrogen
bond
acceptormet
lipophil
interact
ligandprotein
interact
wherea
h
rot
score
repres
loss
conform
entropi
ligand
upon
bind
protein
dg
hbond
dg
metal
dg
lipo
dg
rot
regress
coeffici
deriv
multipl
linear
regress
analysi
train
set
proteinligand
complex
pdb
free
public
databas
zinc
compil
two
million
compound
subset
compound
druglik
properti
satisfi
lipinski
rule
five
select
analysi
databas
use
virtual
screen
select
dock
site
dcir
compound
rank
accord
chemscor
hydrogen
bond
potenti
seven
topscor
compound
identifi
virtual
screen
potenti
inhibitor
attach
dcir
purchas
sigmaaldrich
oakvil
canada
chembridg
san
diego
ca
vitro
screen
use
dcirexpress
cell
model
stock
solut
compound
mm
dmso
prepar
inhibitor
concentr
mm
test
concentr
judg
reason
given
goal
develop
lead
compound
therapeut
potenti
molecul
efficaci
even
lower
concentr
presum
could
deriv
result
present
manuscript
obtain
use
inhibitor
mm
final
dmso
concentr
human
embryon
kidney
hek
cell
cultur
dmem
supplement
fb
cell
line
b
cell
line
carri
epsteinbarr
viru
render
suscept
infect
stabl
transfect
cdna
encod
human
cell
stabli
express
dcir
obtain
follow
retrovir
transduct
describ
previous
experi
also
use
rajidcsign
raji
cell
stabli
transfect
plasmid
encod
dcsign
primari
human
dc
gener
purifi
human
monocyt
ie
cell
peripher
blood
obtain
healthi
donor
cell
cell
isol
fresh
pbmc
use
monocyteposit
select
neg
select
kit
accord
manufactur
instruct
mac
microbead
stemcel
technolog
vancouv
bc
canada
describ
previous
cell
solicit
anonym
healthi
volunt
donor
sign
inform
consent
approv
chul
research
ethic
review
board
produc
upon
transient
transfect
cell
describ
previous
indic
parent
cell
dcirneg
rajidcsign
transfect
pretreat
indic
amount
chemic
inhibitor
min
cell
puls
describ
previous
assess
bindingentri
imddc
cell
final
volum
ml
pretreat
mm
differ
chemic
inhibitor
min
expos
ng
min
three
wash
pb
cell
resuspend
pb
contain
bsa
hiv
capsid
particl
content
determin
elisa
suscept
imddc
infect
assess
initi
expos
cell
ng
h
wash
cell
maintain
complet
rpmi
supplement
gmcsf
plate
final
volum
ml
everi
three
day
nineday
period
half
condit
medium
collect
kept
assay
viru
product
estim
measur
level
elisa
apoptosi
induc
treat
mm
h
h
perform
follow
experiment
procedur
assay
bindingentri
cell
incub
min
ng
three
thorough
wash
pb
remov
unadsorb
viru
bind
quantifi
estim
content
transfer
studi
tran
infect
h
treat
incub
ng
h
wash
autolog
ad
ratio
complet
rpmi
medium
supplement
uml
everi
day
half
condit
medium
collect
kept
cultur
replenish
fresh
medium
studi
viru
product
estim
day
cocultur
measur
level
cellfre
cultur
supernat
statist
analys
carri
accord
method
outlin
zar
sokal
rohlf
use
graphpad
prism
softwar
mean
compar
use
twotail
student
ttest
singlefactor
anova
follow
dunnett
multipl
comparison
two
mean
consid
graph
includ
least
three
experi
perform
triplic
data
present
sem
order
hilight
differ
mean
sem
also
take
sampl
size
account
p
valu
deem
statist
signific
asterisk
denot
statist
signific
differ
identifi
inhibitor
could
prevent
attach
extracellular
domain
dcir
use
virtual
templat
homolog
model
base
lectin
structur
lectin
also
known
lsign
crystal
structur
correspond
fragment
dcsignr
homolog
dcsign
express
epitheli
cell
complex
thu
appear
best
suit
purpos
model
carbohydratebind
domain
defin
residu
dcir
built
refin
use
swiss
model
websit
interfac
amino
acid
residu
model
correspond
dcir
sequenc
shown
figur
propos
tridimension
model
four
beta
sheet
two
alpha
helic
illustr
figur
dock
site
inhibitor
bind
select
number
potenti
site
identifi
site
finder
util
molecular
applic
environ
moe
program
cf
materi
method
primari
target
site
two
hydrophob
pocket
site
associ
crd
domain
locat
near
surfac
delimit
dcir
residu
site
b
associ
ep
motif
nearli
opposit
side
structur
delimit
residu
plu
figur
virtual
screen
inhibitori
compound
perform
site
within
sphere
delimit
radiu
around
atom
residu
site
b
within
sphere
delimit
radiu
around
atom
top
compound
rank
chemscor
function
gold
dock
program
select
visual
inspect
dock
orient
four
compound
select
site
three
site
b
repres
figur
chemic
product
identifi
readili
avail
commerci
vitro
test
use
specif
antibodi
previous
surmis
import
crd
ep
process
attach
rapid
estim
capac
inhibitor
target
structur
alter
initi
step
biolog
cell
stabli
transfect
dcir
use
describ
previous
figur
show
statist
signific
decreas
attach
cell
pretreat
inhibitor
contrast
inhibitor
least
effici
blocker
attach
indic
panel
latter
three
therefor
exclud
studi
order
focu
attent
four
molecul
complet
valid
physiolog
model
primari
cell
dcsign
also
known
play
activ
role
bind
transfer
dc
assess
specif
inhibitor
whether
interact
c
type
lectin
effect
bind
rajidcsign
cell
line
select
compound
screen
test
vitro
chemic
structur
potenti
inhibitor
attach
dcir
select
virtual
screen
compound
select
crd
site
depict
select
ep
site
name
virtual
interact
compound
site
dcir
model
antihiv
activ
b
inhibitor
decreas
attach
dcir
cell
treat
one
four
sitea
inhibitor
one
three
siteb
inhibitor
inhibitor
concentr
mm
solvent
mm
dmso
min
cell
thereaft
expos
viru
min
three
wash
pb
remov
unadsorb
viru
abund
cellassoci
virion
quantifi
measur
content
data
correspond
mean
sem
three
independ
experi
perform
triplic
sampl
asterisk
denot
statist
signific
valu
test
figur
show
inhibitor
affect
bind
dcsign
data
consist
select
inhibitor
specif
dcir
inact
dcsign
despit
fact
lectin
ctype
close
relat
also
crucial
determin
impact
inhibitor
cellular
viabil
peripher
blood
mononuclear
cell
pbmc
preincub
inhibitor
measur
mitogen
stimul
cellular
prolifer
use
mtt
method
figur
show
clearli
inhibitor
affect
cell
prolifer
observ
cell
line
primari
cell
use
studi
decreas
bind
induc
compound
result
disrupt
interact
dcir
mere
consequ
reduc
viabil
data
shown
dose
respons
also
perform
toxic
observ
concentr
mm
four
inhibitor
data
shown
potenti
side
effect
inhibitor
cell
express
larg
amount
dcir
test
result
show
neutrophil
function
respons
degranul
affect
inhibitor
data
shown
observ
strengthen
conclus
inhibitor
seem
specif
toxic
final
impact
inhibitor
express
receptor
coreceptor
dc
assess
cytofluorometri
express
affect
inhibitor
pretreat
data
shown
sinc
attach
dcir
correl
increas
infect
impact
pretreat
select
inhibitor
viral
replic
cell
evalu
figur
show
four
inhibitor
decreas
product
dcirexpress
cell
none
inhibitor
effect
replic
cell
highlight
specif
potenc
dcir
inhibitor
data
show
reduc
attach
decreas
viral
infect
measur
three
day
follow
preincub
drug
candid
note
signific
inhibit
observ
six
nine
day
post
infect
inhibitor
ad
pretreat
determin
dcir
inhibitor
block
interact
dcir
cell
line
express
dcir
valid
activ
select
inhibitor
physiolog
condit
effect
dcir
inhibitor
attach
cisinfect
test
use
dc
figur
dmso
cell
expos
h
rins
maintain
cultur
cellfre
cultur
supernat
collect
assay
content
data
shown
correspond
mean
sem
independ
experi
perform
triplic
sampl
asterisk
denot
statist
signific
valu
figur
show
bind
dc
preincub
four
inhibitor
decreas
significantli
four
inhibitor
also
block
product
infect
day
figur
observ
figur
new
virion
product
day
affect
pretreat
inhibitor
pretreat
hydrogen
peroxid
h
mimic
apoptosi
hallmark
evolut
aid
express
dcir
also
associ
state
promot
tran
infect
shown
previous
sought
confirm
role
dcir
attach
figur
transmiss
figur
via
treat
cell
h
preincub
select
dcir
inhibitor
tran
infect
via
apoptot
figur
show
decreas
attach
h
treat
cell
inhibitor
also
lower
propag
h
treat
activ
figur
prolifer
known
import
replic
observ
inhibitor
affect
cell
prolifer
figur
level
inhibit
obtain
compound
describ
studi
compar
observ
previou
studi
use
antibodi
sirna
intracellular
inhibitor
dcir
surfac
molecul
involv
attach
infect
dc
therefor
expect
observ
complet
inhibit
dc
infect
figur
show
probabl
orient
compound
dock
surfac
model
dcir
molecul
compound
figur
dcir
inhibitor
reduc
attach
infect
primari
dendrit
cell
immddc
treat
four
chemic
inhibitor
dmso
min
next
cell
puls
min
rins
thoroughli
measur
content
b
experi
similarli
treat
immddc
puls
h
rins
thoroughli
maintain
complet
cultur
medium
supplement
gmcsf
day
medium
replenish
everi
day
cellfre
cultur
supernat
quantifi
measur
content
data
shown
correspond
mean
sem
independ
experi
perform
triplic
asterisk
denot
statist
signific
valu
figur
impact
dcir
inhibitor
transmiss
apoptot
cell
target
cell
treat
h
h
mm
induc
apoptosi
surfac
express
dcir
cell
h
treatment
incub
min
site
inhibitor
site
b
inhibitor
mm
dmso
cell
next
expos
h
wash
thoroughli
remov
unadsorb
virion
assess
content
b
cell
first
incub
h
wash
thoroughli
remov
unadsorb
virion
cultur
autolog
complet
supplement
cellfre
supernat
collect
day
assay
content
dock
pocket
form
dock
pocket
line
residu
model
absorpt
distribut
metabol
elimin
toxic
admet
properti
four
best
compound
use
admet
predictor
illustr
figur
toxic
admet
score
summar
risk
low
absorpt
oral
dose
mutagen
activ
overal
toxic
metabol
liabil
low
score
indic
low
predict
toxic
admet
liabil
compar
variou
class
current
prescrib
drug
compound
lower
score
risk
assess
even
better
drug
term
admet
properti
result
encourag
justifi
futur
vivo
assay
despit
great
stride
understand
pathogenesi
immun
protect
pandem
keep
expand
effect
cure
appear
like
becom
avail
near
futur
moreov
drug
develop
far
promot
select
resist
strain
viru
introduct
antiretrovir
therapi
mid
strong
impact
cours
infect
throughout
world
current
avail
treatment
target
differ
step
viral
propag
cycl
entri
host
cell
revers
transcript
integr
protein
matur
led
signific
reduct
hivrel
mortal
although
combin
antiretrovir
drug
haart
therapi
first
met
resound
success
limit
soon
becam
obviou
patient
morbid
enhanc
drugresist
virus
emerg
current
antiretrovir
therapi
actual
erad
viru
bodi
base
major
role
play
dcir
infect
provid
novel
strategi
block
transmiss
dc
well
apoptot
studi
detail
threedimension
structur
dcir
propos
four
inhibitor
direct
crd
domain
ep
motif
dcir
block
replic
propag
identifi
result
clinic
relev
sinc
block
attach
dcir
may
repres
novel
strategi
pathogenesi
inde
prevent
viru
bind
dcir
could
lead
signific
decreas
transmiss
primari
infect
period
viru
dissemin
mucos
dc
express
dcir
ultim
transfer
addit
dcir
inhibitor
reduc
product
therefor
use
prophylaxisprimo
infect
therapeut
stage
infect
discoveri
new
therapeut
target
develop
new
approach
treatment
necessari
order
pursu
fight
new
class
inhibitor
target
cellular
partner
hiv
virion
develop
includ
integras
inhibitor
antagonist
coreceptor
one
alreadi
commerci
avail
matur
process
inhibitor
cdk
inhibitor
antibodi
new
attach
factor
inhibitor
antidcsign
antagonist
molecul
target
dcsign
interfer
bind
interact
viral
mannosebind
lectin
express
cell
mucos
tissu
thu
facilit
transmiss
inhibitor
interact
therefor
use
primarili
prevent
infect
sinc
dcsign
known
involv
transinfect
dc
success
preexposur
prophylaxi
prep
valid
import
act
earli
argu
haas
spite
intens
competit
drug
market
kalorama
hivaid
market
discoveri
new
target
new
molecul
select
resist
form
viru
block
tropic
virion
continu
lag
molecul
target
dcir
use
block
initi
step
infect
effect
well
addit
specif
express
infect
apoptot
make
dcir
interest
potenti
target
treatment
infect
vitro
test
molecul
target
dcir
show
four
five
candid
select
chemscor
rank
activ
inhibitor
bind
indic
dcir
dock
platform
set
interest
potenti
improv
select
inhibitor
specif
interact
virtual
model
screen
process
close
match
actual
dcir
structur
initi
screen
inhibitor
inhibitori
activ
bind
prior
perform
vitro
experi
transfect
either
dcir
vector
among
seri
compound
ie
direct
crd
domain
compound
weakli
inhibitori
bind
direct
ep
motif
rel
strong
inhibitor
interestingli
two
activ
inhibitor
differ
structur
direct
differ
motif
henc
specif
site
action
base
model
addit
inhibitor
impact
express
coreceptor
data
shown
vitro
experi
rajidcsign
evalu
specif
inhibitor
confirm
block
attach
dcsign
latter
ctype
lectin
known
bind
sever
type
virus
base
result
suggest
inhibitor
thu
select
like
specif
attach
dcir
addit
select
compound
show
predict
toxic
measur
admet
better
current
prescrib
drug
confirm
cellular
level
toxic
test
physiolog
relev
analysi
activ
inhibitor
carriedout
use
two
major
cell
type
involv
pathogenesi
dc
inhibitor
display
specif
inhibit
attach
subsequ
infect
immatur
monocytederiv
dendrit
cell
imddc
previous
show
express
dcir
patient
dcir
express
increas
infecti
process
promot
transinfect
transmiss
bystand
cell
dcir
appear
specif
link
infecti
process
cell
apoptosi
import
sinc
previou
studi
suggest
direct
correl
degre
apoptosi
among
circul
pathogenesi
result
present
studi
demonstr
select
dcirtarget
inhibitor
effect
model
resembl
chronic
phase
infect
base
preliminari
observ
predict
inhibitor
design
bind
specif
crd
domain
ep
motif
dcir
decreas
attach
dc
primari
infect
result
reduc
dc
infect
develop
novel
therapeut
drug
infect
one
must
consid
mechan
viral
replic
insid
also
insid
dc
agre
haas
crucial
find
appropri
way
mean
allevi
viral
load
allow
proper
mount
specif
immun
respons
crucial
earli
phase
avoid
irrevers
damag
immun
system
chronic
phase
allow
immun
system
mount
effect
defenc
futur
design
new
drug
infect
focu
prevent
irrevers
impair
immun
system
inde
current
use
drug
block
late
stage
viral
life
cycl
provid
protect
earlier
damag
result
immunodefici
caus
target
ctype
dcir
lectin
found
dc
well
approach
describ
report
provid
potenti
avenu
effect
interfer
initi
propag
earli
stage
viral
cycl
limit
prolifer
viru
later
stage
extens
vivo
valid
nevertheless
remain
perform
order
valid
target
dcir
therapeut
approach
well
safeti
drug
use
purpos
